Under a new agreement, Destiny Pharma and Sebela Pharmaceuticals will co-develop NTCD-M3, Destiny’s lead asset for the prevention of Clostridioides difficile infection (CDI) recurrence. It is anticipated that Sebela will lead and finance the future clinical development and commercialisation activities of NTCD-M3 in North America. Destiny will keep most rights for Europe and Rest of […]
Menu ≡ ╳ 
